|
 |
| |
| |
| Licensing & Royalties >> Licensing Opportunities >> Abstract Details |
|
| |
| Compounds Binding to the N-Terminal Domains of STAT Proteins as Therapeutic Agents |
Description of Invention:
Signal transducer and activator transcription (STAT) proteins, specifically STAT1, 2, 3, 4, 5a, 5b, and 6, are involved in the cellular and biological processes of cell proliferation, differentiation, apoptosis, host defense, and transformation. Constitutively active STAT proteins occur in many human tumor cells and cells transformed by oncoproteins. Inhibiting these STAT proteins has great therapeutic potential in the treatment of certain cancers.
The current invention describes a family of short peptides that bind to the N-terminus domains of STAT proteins and their use as therapeutic agents. These compounds are the first inhibitors that can directly bind to N-domains of STATs and exhibit a direct inhibitory effect. STAT1, 3, and 5 inhibitors can serve as potent therapeutic agents for the treatment of a variety of tumors and STAT 4 inhibitors can be used to control autoimmune disorders.
Applications:
- Using STAT1, STAT3 and STAT5 inhibitors for the treatment of various tumors
- Using STAT4 inhibitors to control autoimmune disorders
- Using STAT inhibitors as research tools to study the function of STAT proteins
Development Status:
Pre-clinical
Inventors:
Nadya I Tarasova (NCI)
Patent Status:
HHS, Reference No. E-164-2007/0
US, Application No. 12/601,711 filed 05 Feb 2010
Relevant Publication:
- A manuscript directly related to the above technology will be available as soon as it is accepted for publication.
Collaborative Research Opportunity:
The National Cancer Institute Cancer and Inflammation Program is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize inhibitors of STAT proteins for the treatment of cancer. For collaboration opportunities, please contact John Hewes, Ph.D. at hewesj@mail.nih.gov. Click here to view the NCI collaborative opportunity announcement.
For Licensing Information Please Contact:
Jennifer Wong
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: wongje@mail.nih.gov
Phone: 301-435-4633
Fax: 301-402-0220
Ref No: 1573
Updated: 02/2013
|
|
|
|
| |
|
|
|
|